423 related articles for article (PubMed ID: 33076914)
1. Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study.
Veit T; Barnikel M; Crispin A; Kneidinger N; Ceelen F; Arnold P; Munker D; Schmitzer M; Barton J; Schiopu S; Schiller HB; Frankenberger M; Milger K; Behr J; Neurohr C; Leuschner G
Respir Res; 2020 Oct; 21(1):270. PubMed ID: 33076914
[TBL] [Abstract][Full Text] [Related]
2. Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study.
Wijsenbeek MS; Bendstrup E; Valenzuela C; Henry MT; Moor CC; Jouneau S; Fois AG; Moran-Mendoza O; Anees S; Mirt M; Bengus M; Gilberg F; Kirchgaessler KU; Vancheri C
Adv Ther; 2021 Jul; 38(7):4040-4056. PubMed ID: 34117601
[TBL] [Abstract][Full Text] [Related]
3. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
[TBL] [Abstract][Full Text] [Related]
4. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
[TBL] [Abstract][Full Text] [Related]
5. Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis.
Russell AM; Adamali H; Molyneaux PL; Lukey PT; Marshall RP; Renzoni EA; Wells AU; Maher TM
Am J Respir Crit Care Med; 2016 Oct; 194(8):989-997. PubMed ID: 27089018
[TBL] [Abstract][Full Text] [Related]
6. A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease.
Maher TM; Schiffman C; Kreuter M; Moor CC; Nathan SD; Axmann J; Belloni P; Bengus M; Gilberg F; Kirchgaessler KU; Wijsenbeek MS
Respir Res; 2022 Nov; 23(1):307. PubMed ID: 36369156
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and acceptability of remotely monitoring spirometry and pulse oximetry as part of interstitial lung disease clinical care: a single arm observational study.
Barth S; Edwards C; Saini G; Haider Y; Williams NP; Storrar W; Jenkins G; Stewart I; Wickremasinghe M
Respir Res; 2024 Apr; 25(1):162. PubMed ID: 38622608
[TBL] [Abstract][Full Text] [Related]
8. Using forced vital capacity (FVC) in the clinic to monitor patients with idiopathic pulmonary fibrosis (IPF): pros and cons.
Nathan SD; Wanger J; Zibrak JD; Wencel ML; Burg C; Stauffer JL
Expert Rev Respir Med; 2021 Feb; 15(2):175-181. PubMed ID: 32985286
[TBL] [Abstract][Full Text] [Related]
9. Disease trajectories in interstitial lung diseases - data from the EXCITING-ILD registry.
Buschulte K; Kabitz HJ; Hagmeyer L; Hammerl P; Esselmann A; Wiederhold C; Skowasch D; Stolpe C; Joest M; Veitshans S; Höffgen M; Maqhuzu P; Schwarzkopf L; Hellmann A; Pfeifer M; Behr J; Karpavicius R; Günther A; Polke M; Höger P; Somogyi V; Lederer C; Markart P; Kreuter M
Respir Res; 2024 Mar; 25(1):113. PubMed ID: 38448953
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.
Hambly N; Farooqi MM; Dvorkin-Gheva A; Donohoe K; Garlick K; Scallan C; Chong SG; MacIsaac S; Assayag D; Johannson KA; Fell CD; Marcoux V; Manganas H; Morisset J; Comes A; Fisher JH; Shapera S; Gershon AS; To T; Wong AW; Sadatsafavi M; Wilcox PG; Halayko AJ; Khalil N; Cox G; Richeldi L; Ryerson CJ; Kolb M
Eur Respir J; 2022 Oct; 60(4):. PubMed ID: 35273032
[TBL] [Abstract][Full Text] [Related]
11. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.
Reichmann WM; Yu YF; Macaulay D; Wu EQ; Nathan SD
BMC Pulm Med; 2015 Dec; 15():167. PubMed ID: 26714746
[TBL] [Abstract][Full Text] [Related]
12. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database.
Hoffmann-Vold AM; Allanore Y; Alves M; Brunborg C; Airó P; Ananieva LP; Czirják L; Guiducci S; Hachulla E; Li M; Mihai C; Riemekasten G; Sfikakis PP; Kowal-Bielecka O; Riccardi A; Distler O;
Ann Rheum Dis; 2021 Feb; 80(2):219-227. PubMed ID: 32988845
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of online home spirometry in systemic sclerosis-associated interstitial lung disease: a pilot study.
Moor CC; van Leuven SI; Wijsenbeek MS; Vonk MC
Rheumatology (Oxford); 2021 May; 60(5):2467-2471. PubMed ID: 33212511
[TBL] [Abstract][Full Text] [Related]
14. [Characteristics and clinical significance of pulmonary function test and KL-6 in ASSD-ILD and IPF].
Sun D; Cheng Z; Jiang TC; Li PF; Jia LQ; Wang TT; Zheng CP; Li Y; Duo MJ
Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(10):748-752. PubMed ID: 32192286
[No Abstract] [Full Text] [Related]
15. A simple dyspnoea scale as part of the assessment to predict outcome across chronic interstitial lung disease.
Khadawardi H; Mura M
Respirology; 2017 Apr; 22(3):501-507. PubMed ID: 27862639
[TBL] [Abstract][Full Text] [Related]
16. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study).
Nasser M; Larrieu S; Si-Mohamed S; Ahmad K; Boussel L; Brevet M; Chalabreysse L; Fabre C; Marque S; Revel D; Thivolet-Bejui F; Traclet J; Zeghmar S; Maucort-Boulch D; Cottin V
Eur Respir J; 2021 Feb; 57(2):. PubMed ID: 32943410
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
18. Reticulation pattern without honeycombing on high-resolution CT is associated with the risk of disease progression in interstitial lung diseases.
Mononen M; Saari E; Hasala H; Kettunen HP; Suoranta S; Nurmi H; Kärkkäinen M; Selander T; Randell J; Laurikka J; Uibu T; Koskela H; Kaarteenaho R; Purokivi M
BMC Pulm Med; 2022 Aug; 22(1):313. PubMed ID: 35965320
[TBL] [Abstract][Full Text] [Related]
19. Progressive fibrosing interstitial lung disease: prevalence and clinical outcome.
Kwon BS; Choe J; Chae EJ; Hwang HS; Kim YG; Song JW
Respir Res; 2021 Oct; 22(1):282. PubMed ID: 34719401
[TBL] [Abstract][Full Text] [Related]
20. Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis.
Zhang XJ; Bonner A; Hudson M; ; Baron M; Pope J
J Rheumatol; 2013 Jun; 40(6):850-8. PubMed ID: 23547215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
